Rafael Amado
Equibles does not estimate personal net worth.
About Rafael Amado
Allogene Therapeutics, Inc. reported in an 8-K filed January 3, 2023 that Rafael Amado resigned as Executive Vice President of Research and Development, effective December 30, 2022. The proxy statement of Allogene Therapeutics, Inc. reports total compensation of $5,244,710 for Rafael Amado in fiscal 2022, including a base salary of $633,627. Disclosed compensation is on record for 4 fiscal years.
“On December 27, 2022, Rafael G. Amado, M.D., the Executive Vice President of Research and Development of Allogene Therapeutics, Inc. (the "Company"), notified the Company of his decision to resign, effective December 30, 2022, to pursue another opportunity.”
Affiliation history
-
Allogene Therapeutics, Inc. (ALLO)
Source not stated
Start not stated–2022-12-30
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Allogene Therapeutics, Inc. (ALLO) | Former Executive Vice President of Research and Development | $633,627 | $5,244,710 |
| 2021 | Allogene Therapeutics, Inc. (ALLO) | Former Executive Vice President of Research and Development | $571,591 | $9,714,156 |
| 2020 | Allogene Therapeutics, Inc. (ALLO) | Former Executive Vice President of Research and Development | $510,000 | $2,663,819 |
| 2019 | Allogene Therapeutics, Inc. (ALLO) | Chief Medical Officer and Executive Vice President of Research and Development | $145,833 | $7,452,158 |